Atara Biotherapeutics, Inc. (ATRA) 

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Show less

Over the last 12 months, insiders at Atara Biotherapeutics, Inc. have bought $0 and sold $269,243 worth of Atara Biotherapeutics, Inc. stock.

On average, over the past 5 years, insiders at Atara Biotherapeutics, Inc. have bought $347,627 and sold $1.04M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 90,980 shares for transaction amount of $28,186 was made by Gallagher Carol Giltner (director) on 2023‑11‑14.